Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: FNS who wrote (142)	8/13/1997 9:19:00 PM
From: Thean	of 965

FNS, I believe CNTO is conducting a cost effectiveness analysis and will use that data to arrive at an acceptable pricing for Reopro. It is highly doubtful FDA will use the cost effectiveness data to decide the approvability of Reopro's expanded indication. That does not mean Reopro will have commercial success even if approved, unless Reopro is priced right for the hospital, MCO, etc. Any idea on the exact timing on when this expanded indication will be up for FDA approval decision?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next